Skip to main content
. Author manuscript; available in PMC: 2017 May 11.
Published in final edited form as: Gene Ther. 2016 Nov 11;24(1):49–59. doi: 10.1038/gt.2016.75

Fig. 8. Improvement of phenotypic correction of hemophilia B using human albumin incubated AAV vector.

Fig. 8

2×109 particles of AAV8/FIX-opt vector were incubated with human HSA or PBS for 2 hr at 4 °C, then AAV vector was administered into adult male FIX deficient mice via tail vein injection. Post AAV injection, blood was collected at indicated time points for FIX expression (a) and function assay (b). At week 6 post AAV injection, mice were applied for in vivo bleeding assay (c). (*) indicates statistically significant difference for blood loss between HSA treated mice and PBS mice with p<0.05. The data are based on the average and standard deviations from 6 to 8 mice.